|By PR Newswire||
|August 18, 2014 04:43 PM EDT||
LOS ALTOS, Calif., Aug. 18, 2014 /PRNewswire/ -- Globavir Biosciences, Inc. ("Globavir"), a biotechnology company developing therapeutics to treat infectious diseases, has announced intentions to develop its lead drug candidate, GBV006, for the treatment of the current Ebola Virus outbreak in West Africa. Globavir will seek approval for the use of GBV006, a combination of Food and Drug Administration (FDA) approved drugs, through an established compassionate use regulatory pathway. The discovery of the use of GBV006 for the treatment of infectious diseases was made at Stanford University School of Medicine (Palo Alto, CA). Globavir has the worldwide exclusive license to develop and market GBV006.
The component drugs of GBV006 have demonstrated efficacy against experimental models of Ebola infection at dosages already approved and well-tolerated by patients. GBV006 is effective at low micromolar concentrations against Ebola in vitro. By relying on thousands of patient years of established safety data, Globavir hopes to rapidly introduce GBV006 as an experimental treatment in helping to control the West Africa outbreak.
"The situation in West Africa is dire, and there is an immediate need for drugs able to reduce the impact of Ebola infection," said Shalabh Gupta, M.D., CEO of Globavir. "By repurposing a combination of approved drugs to treat Ebola virus, Globavir has the potential to overcome many hurdles regarding safety and supply of experimental therapies. We hope to quickly form partnerships to distribute this potentially life-saving drug to those who need it most."
Globavir's antiviral therapeutic platform has multiple drugs under development, which were discovered, tested and licensed from Stanford University. The company is evaluating several drug combinations for Ebola treatment.
GBV006 targets and inhibits several distinct stages of the viral lifecycle, including entry of the virus into the cell and maturation of new viruses within cells. These two processes are crucial to viral infections including Ebola, Dengue, and West Nile virus. A distinctive feature of Globavir's technology as compared to other upcoming treatments in the area is that GBV006 targets human cellular machinery necessary for viral replication rather than targeting the viral proteins or DNA directly. As a result, the technology can be utilized to treat diseases caused by different viruses within the same family or those that exploit the same host machinery for entry and replication. A similar approach using GBV001 (a related therapy under development) has shown efficacy in animal models of Dengue virus infection and approval to begin clinical trials will be sought this fall.
Infection with the Ebola virus causes severe hemorrhagic fever and causes death in up to 90% of cases. Ebola virus is a member of the family of RNA viruses known as Filoviridae. Ebola transmission occurs through contact with bodily fluid of an infected patient and there is no currently available treatment for Ebola beyond supportive care.
Globavir's lead therapeutic program has focused on the treatment of Dengue Fever, which is caused by Flaviviridae, another family of RNA viruses. Both Ebola and Dengue Fever can cause a syndrome known as viral hemorrhagic fever, a severe illness associated with bleeding.
A recent outbreak of Ebola in West Africa has killed over 1000 people, and is the largest outbreak recorded.
Globavir Biosciences is an infectious disease company developing life-saving technologies for the diagnosis and treatment of some of the world's most deadly viral diseases. Globavir is developing powerful combination drug therapies and diagnostic tests for the treatment of Dengue Fever, and is advancing a development candidate for the treatment of Ebola, GBV006. Globavir is based out of Mountain View, California, USA, and has additional research facilities in Halifax, Nova Scotia, Canada operating as BioCycive Canada.
Globavir's diagnostic tests and test kits are ready to be marketed globally. The company has the leading blood-based molecular diagnostic test to detect Dengue infection as well as a platform for other viral detection tests.
Forward Looking Statements and Information
In order to provide Globavir's investors with an understanding of its current results and future prospects, this press release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward looking statements. Words such as "believes," "anticipates," "hopes," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements about the development of Globavir's product candidates, their efficacy, potency and utility in the treatment of rare and infectious diseases, their potential to treat a broad number of human diseases and Globavir's studies. These forward-looking statements involve risks and uncertainties, many of which are beyond Globavir's control. Known risk factors include, among others: clinical trials may not demonstrate safety and efficacy of any of Globavir's drug candidates and/or Globavir's technology platform; and any of Globavir's drug candidates may fail in development, may not receive required regulatory approvals, or be delayed to a point where they do not become commercially viable. Any of the foregoing risks could materially and adversely affect Globavir's business results.
Globavir does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
SOURCE Globavir Biosciences, Inc.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading in...
May. 23, 2015 11:30 AM EDT Reads: 2,279
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo, June 9-11, 2015, at the Javits Center in New York City. Learn what is going on, contribute to the discussions, and ensure that your enter...
May. 23, 2015 11:15 AM EDT Reads: 1,542
The Internet of Things is a misnomer. That implies that everything is on the Internet, and that simply should not be - especially for things that are blurring the line between medical devices that stimulate like a pacemaker and quantified self-sensors like a pedometer or pulse tracker. The mesh of things that we manage must be segmented into zones of trust for sensing data, transmitting data, receiving command and control administrative changes, and peer-to-peer mesh messaging. In his session a...
May. 23, 2015 11:00 AM EDT Reads: 3,677
SYS-CON Events announced today that EnterpriseDB (EDB), the leading worldwide provider of enterprise-class Postgres products and database compatibility solutions, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. EDB is the largest provider of Postgres software and services that provides enterprise-class performance and scalability and the open source freedom to divert budget from more costly traditiona...
May. 23, 2015 11:00 AM EDT Reads: 1,347
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
May. 23, 2015 11:00 AM EDT Reads: 624
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
May. 23, 2015 11:00 AM EDT Reads: 5,357
Organizations today are confounded by an avalanche of data that needs to be processed and managed on a daily basis. Through relevant use cases and a thought-provoking dialogue on an organization’s ‘Data to Decisions’ journey, Andrew Clyne, Chief Data Officer at CenturyLink Cognilytics, will reveal in his session at Big Data Expo how your organization can monetize data as a strategic asset. State-of-the-art Big Data and Advanced Analytics capabilities provided as a managed service can enable da...
May. 23, 2015 10:45 AM EDT Reads: 1,492
There is no doubt that Big Data is here and getting bigger every day. Building a Big Data infrastructure today is no easy task. There are an enormous number of choices for database engines and technologies. To make things even more challenging, requirements are getting more sophisticated, and the standard paradigm of supporting historical analytics queries is often just one facet of what is needed. As Big Data growth continues, organizations are demanding real-time access to data, allowing immed...
May. 23, 2015 10:30 AM EDT Reads: 2,608
We are all here because we are sold on the transformative promise of The Cloud. But what good is all of this ephemeral, on-demand infrastructure if your usage doesn't actually improve the agility and speed of your business? How must Operations adapt in order to avoid stifling your Cloud initiative? In his session at DevOps Summit, Damon Edwards, co-founder and managing partner of the DTO Solutions, will highlight the successful organizational, process, and tooling patterns of high-performing c...
May. 23, 2015 10:00 AM EDT Reads: 5,233
SYS-CON Events announced today that the "First Containers & Microservices Conference" will take place June 9-11, 2015, at the Javits Center in New York City. The “Second Containers & Microservices Conference” will take place November 3-5, 2015, at Santa Clara Convention Center, Santa Clara, CA. Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities.
May. 23, 2015 10:00 AM EDT Reads: 1,744
There is no question that the cloud is where businesses want to host data. Until recently hypervisor virtualization was the most widely used method in cloud computing. Recently virtual containers have been gaining in popularity, and for good reason. In the debate between virtual machines and containers, the latter have been seen as the new kid on the block – and like other emerging technology have had some initial shortcomings. However, the container space has evolved drastically since coming on...
May. 23, 2015 10:00 AM EDT Reads: 902
With worldwide spending on cloud services and infrastructure growing by 23% in 2015 to $118B, it is clear that cloud services are here to stay. Yet, the rate of cloud adoption varies by companies and markets around the world. With thousands of outages and hijacks across the Internet every day, one reason for hesitation is the faith in quality Internet performance. In his session at 16th Cloud Expo, Michael Kane, Senior Manager at Dyn, will explore how Internet performance affects your end-user...
May. 23, 2015 10:00 AM EDT Reads: 1,268
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? In this Power Panel at DevOps Summit, moderated by Jason Bloomberg, the leading expert on architecting agility for the enterprise and president of Intellyx, panelists will peel away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud en...
May. 23, 2015 10:00 AM EDT Reads: 1,640
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between confe...
May. 23, 2015 10:00 AM EDT Reads: 2,847
Data-intensive companies that strive to gain insights from data using Big Data analytics tools can gain tremendous competitive advantage by deploying data-centric storage. Organizations generate large volumes of data, the vast majority of which is unstructured. As the volume and velocity of this unstructured data increases, the costs, risks and usability challenges associated with managing the unstructured data (regardless of file type, size or device) increases simultaneously, including end-to-...
May. 23, 2015 09:30 AM EDT Reads: 4,058